Friday, 16 October 2026European Markets

MPC CONTAINER SHIP And GL EVENTS Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(vianews) - mpc container ship (mpcc.ol) is among this list of stock assets with the highest dividend rate and return on equity on the industrials sector.

financial asset price forward dividend yield return on equity
mpc container ship (mpcc.ol) kr14.20 45.55% 52.99%
gl events (glo.pa) €19.52 2.27% 14.31%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. mpc container ship (mpcc.ol)

45.55% forward dividend yield and 52.99% return on equity

mpc container ships asa owns and operates a portfolio of container vessels. the company focuses on small-to mid-size vessels that are chartered out on time-charter contracts to global and regional liner shipping companies serving intra-regional trade lanes. it operates a fleet of 62 vessels with an aggregate capacity of approximately 134,270 twenty-foot equivalent units. mpc container ships asa was incorporated in 2017 and is based in oslo, norway.

earnings per share

as for profitability, mpc container ship has a trailing twelve months eps of kr9.04.

pe ratio

mpc container ship has a trailing twelve months price to earnings ratio of 1.57. meaning, the purchaser of the share is investing kr1.57 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 52.99%.

growth estimates quarters

the company's growth estimates for the ongoing quarter and the next is a negative 30.4% and a negative 25%, respectively.

more news about mpc container ship.

2. gl events (glo.pa)

2.27% forward dividend yield and 14.31% return on equity

gl events sa provides venues and offices for events. it operates through three divisions: gl events live, gl events exhibitions, and gl events venues. the gl events live division offers various business line specializations and services, including turnkey solutions, designing, consulting, and staging the events for corporate, institutional, and sports events. the gl events exhibitions division manages and coordinates a portfolio of trade shows and consumer fairs in various sectors, such as food, culture, textile, etc. the gl events venues division manages a network of venues that include convention centers, exhibition centers, concert halls, and multi-purpose facilities. the company was formerly known as générale location and changed its name to gl events sa in 2003. the company was founded in 1978 and is headquartered in lyon, france. gl events sa is a subsidiary of polygone sa.

earnings per share

as for profitability, gl events has a trailing twelve months eps of €2.25.

pe ratio

gl events has a trailing twelve months price to earnings ratio of 8.68. meaning, the purchaser of the share is investing €8.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.31%.

more news about gl events.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com